Ask the Expert: Dr. Pravesh Gupta answers key questions from his ongoing myeloid cell research and recent webinar.
Ask the Expert: Mike Ritchie, PhD, MBA, answers key questions about our new bioinformatics platform, LUMIN, from his recent webinar.
Chelsea Riveley, MBA, answers key questions about Flow Cytometry in a non-regulatory and regulatory environment from her recent webinar.
How important is the validation step in the clinical setting? Are there different validations parameters depending on the complexity of the assay and/or on the clinical trial phase?
Amy Wesa, PhD, answers key questions about immuno-oncology and the current ex vivo platforms that are available at Champions Oncology, and were discussed in detail in her recent webinar.
- Does Champions have the ability to test immuno-oncology agents in these platforms?Champions has extensive experience in humanized mouse models in solid tumor PDX and has a group of scientists with deep immuno-oncology know-how. We are actively developing platforms for evaluating IO agents in the context hematologic malignancy models and welcome the opportunity to develop custom assays as well.
Ask an Expert: Dr. Tamara Laskowski, Senior Research Scientist from MD Anderson Cancer Center, answers key questions from her recent webinar.
- How long does it take to understand an assay from design to good reproductible data?
It will depend on a few factors such as 1) The level of training of the person who is developing the assay, 2) The complexity of the assay they are developing, and 3) The support they have (e.g. mentors, peers who have advanced knowledge, ease of access to cytometer).
If the user has some experience with flow cytometry and panel design, and has a good level of support, for a 5-7 color assay, in 2-3 weeks you should be able to have a panel designed, antibodies ordered, titrations performed, controls selected, single-color and biological controls empirically tested.
